Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$211.57M$211.57Mderived+21.5% vs Q4 2024 Net Income-$4.11M-$4.11MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,937,000N/M Operating Cash Flowderived$19,861,000−55.3% Free Cash Flowderived$19,434,000−56.0% Margins · derivedOperating margin-1.9%−14.2 pt vs Q4 2024
Net margin-1.9%−10.7 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 2, 2026 · 61 d after period end